Impact of 10- and 13-valent pneumococcal conjugate vaccines on incidence of invasive pneumococcal disease in children aged under 16 years in Germany, 2009 to 2012-Reference-Cited by-同舟云学术

Impact of 10- and 13-valent pneumococcal conjugate vaccines on incidence of invasive pneumococcal disease in children aged under 16 years in Germany, 2009 to 2012

Published:2015-03-12 Issue:10 Volume:20 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Weiss S¹,Falkenhorst G²,van der Linden M³,Imöhl M³,von Kries R¹

Affiliation:

1. Ludwig-Maximilians-University of Munich, Institute of Social Paediatrics and Adolescent Medicine, Munich, Germany

2. Robert Koch Institute, Department for Infectious Disease Epidemiology, Berlin, Germany

3. National Reference Centre for Streptococci, Institute of Medical Microbiology, University Hospital RWTH Aachen, Aachen, Germany

Abstract

Binary file ES_Abstracts_Final_ECDC.txt matches

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference24 articles.

1. Robert Koch Institute (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Begründungen zur allgemeinen Empfehlung der Impfungen gegen Pneumokokken und Meningokokken im Säuglings- und Kindesalter. [Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute: Scientific justification for the universal recommendation to vaccinate against pneumoccal and meningococcal disease during infancy and childhood]. Epidemiologisches Bulletin. 2006;31:255-60. Berlin: RKI; 2006. German. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2006/Ausgabenlinks/31_06.pdf?__blob=publicationFile

2. Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children

3. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517.http://dx.doi.org/10.1371/journal.pmed.1001517 PMID:24086113

4. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127-31.http://dx.doi.org/10.1016/j.vaccine.2011.09.112 PMID:21983361

5. Göbel U, Heinrich B, Krauth KA, Steingrüber HJ, von Kries R. [Process and outcome quality of the German Paediatric Surveillance Unit (ESPED)]. Klin Padiatr. 2010;222(2):92-7. German. PMID:20146163

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis;Infectious Diseases and Therapy;2024-05-11

2. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population - A German Societal Perspective Analysis;2024-03-15

3. Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs;PLOS ONE;2023-02-15

4. Characteristics of Clonal Complex Changes and Quinolone Resistance-Determining Region Mutations of Levofloxacin-Resistant Streptococcus pneumoniae in South Korea;Microbial Drug Resistance;2022-05-01

5. Potential impact of combined influenza and pneumococcal vaccines on the severity of respiratory illness in COVID-19 infection among type 2 diabetic patients;Clinical and Experimental Medicine;2022-01-22